Literature DB >> 20005966

Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation.

Stefan O Ciurea1, Marcos de Lima, Sergio Giralt, Rima Saliba, Carlos Bueso-Ramos, Borje S Andersson, Chitra M Hosing, Srdan Verstovsek, Richard E Champlin, Uday Popat.   

Abstract

Leukemic transformation (LT) from myelofibrosis has a very poor prognosis with the current treatment strategies. We hypothesized that allogeneic stem cell transplantation (ASCT) can improve outcomes for patients with LT, and reviewed 55 consecutive patients that were treated for myelofibrosis with ASCT at our institution. Fourteen patients (25%) were identified to have LT. Thirteen of these patients received induction chemotherapy and 6 achieved remission at the time of transplant. Conditioning regimen was melphalan (Mel)-based in 9 patients. All patients engrafted and achieved remission after transplant, whereas 4 subsequently relapsed. After a median follow-up of 31 months, 6 patients (49%) survived long term. Although limited by a small number of patients, this study suggests that patients with myelofibrosis and LT may achieve long-term remission after induction chemotherapy and ASCT. Copyright (c) 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20005966      PMCID: PMC4352934          DOI: 10.1016/j.bbmt.2009.12.004

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  21 in total

Review 1.  Chronic graft-versus-host disease and other late complications of bone marrow transplantation.

Authors:  K M Sullivan; E Agura; C Anasetti; F Appelbaum; C Badger; S Bearman; K Erickson; M Flowers; J Hansen; T Loughran
Journal:  Semin Hematol       Date:  1991-07       Impact factor: 3.851

2.  Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia.

Authors:  M Jurado; H Deeg; T Gooley; C Anasetti; T Chauncey; M Flowers; D Myerson; R Storb; F Appelbaum
Journal:  Br J Haematol       Date:  2001-02       Impact factor: 6.998

3.  Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study.

Authors:  P Guardiola; J E Anderson; G Bandini; F Cervantes; V Runde; W Arcese; A Bacigalupo; D Przepiorka; M R O'Donnell; P Polchi; A Buzyn; L Sutton; D Cazals-Hatem; G Sale; T de Witte; H J Deeg; E Gluckman
Journal:  Blood       Date:  1999-05-01       Impact factor: 22.113

4.  Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia.

Authors:  Damiano Rondelli; Giovanni Barosi; Andrea Bacigalupo; Josef T Prchal; Uday Popat; Emilio P Alessandrino; Jerry L Spivak; B Douglas Smith; Hans G Klingemann; Steven Fruchtman; Ronald Hoffman
Journal:  Blood       Date:  2005-01-25       Impact factor: 22.113

5.  Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.

Authors:  B Dupriez; P Morel; J L Demory; J L Lai; M Simon; I Plantier; F Bauters
Journal:  Blood       Date:  1996-08-01       Impact factor: 22.113

6.  JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

Authors:  Giovanni Barosi; Gaetano Bergamaschi; Monia Marchetti; Alessandro M Vannucchi; Paola Guglielmelli; Elisabetta Antonioli; Margherita Massa; Vittorio Rosti; Rita Campanelli; Laura Villani; Gianluca Viarengo; Elisabetta Gattoni; Giancarla Gerli; Giorgina Specchia; Carmine Tinelli; Alessandro Rambaldi; Tiziano Barbui
Journal:  Blood       Date:  2007-08-21       Impact factor: 22.113

7.  Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis.

Authors:  Stefan O Ciurea; Delwin Merchant; Nadim Mahmud; Takefumi Ishii; Yan Zhao; Wenyang Hu; Edward Bruno; Giovanni Barosi; Mingjiang Xu; Ronald Hoffman
Journal:  Blood       Date:  2007-05-01       Impact factor: 22.113

8.  The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.

Authors:  Constantine S Tam; Roberto M Nussenzveig; Uday Popat; Carlos E Bueso-Ramos; Deborah A Thomas; Jorge A Cortes; Richard E Champlin; Stefan E Ciurea; Taghi Manshouri; Sherry M Pierce; Hagop M Kantarjian; Srdan Verstovsek
Journal:  Blood       Date:  2008-06-19       Impact factor: 22.113

9.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

Authors:  Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi
Journal:  Blood       Date:  2008-11-06       Impact factor: 22.113

Review 10.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

View more
  13 in total

1.  Myelofibrosis 2012: it's complicated.

Authors:  Harper G Hubbeling; Dale M Frank; Elizabeth O Hexner
Journal:  Ther Adv Hematol       Date:  2012-06

Review 2.  Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.

Authors:  N M Kröger; J H Deeg; E Olavarria; D Niederwieser; A Bacigalupo; T Barbui; A Rambaldi; R Mesa; A Tefferi; M Griesshammer; V Gupta; C Harrison; H Alchalby; A M Vannucchi; F Cervantes; M Robin; M Ditschkowski; V Fauble; D McLornan; K Ballen; U R Popat; F Passamonti; D Rondelli; G Barosi
Journal:  Leukemia       Date:  2015-08-21       Impact factor: 11.528

3.  Allo-SCT for  Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC).

Authors:  X Cahu; P Chevallier; A Clavert; F Suarez; M Michallet; L Vincent; S Vigouroux; D Blaise; C Mariette; K Bilger; M Robin; I Yakoub-Agha; R Peffault de Latour; M Mohty
Journal:  Bone Marrow Transplant       Date:  2014-03-10       Impact factor: 5.483

Review 4.  Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups.

Authors:  H Joachim Deeg; Christopher Bredeson; Stephanie Farnia; Karen Ballen; Vikas Gupta; Ruben A Mesa; Uday Popat; Parameswaran Hari; Wael Saber; Matthew Seftel; Roni Tamari; Effie W Petersdorf
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-11       Impact factor: 5.742

5.  Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.

Authors:  John Mascarenhas; Mark L Heaney; Vesna Najfeld; Elizabeth Hexner; Omar Abdel-Wahab; Raajit Rampal; Farhad Ravandi; Bruce Petersen; Gail Roboz; Eric Feldman; Nikolai Podoltsev; Dan Douer; Ross Levine; Martin Tallman; Ronald Hoffman
Journal:  Leuk Res       Date:  2012-08-28       Impact factor: 3.156

Review 6.  Leukemia secondary to myeloproliferative neoplasms.

Authors:  Andrew J Dunbar; Raajit K Rampal; Ross Levine
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

Review 7.  Current Challenges in Stem Cell Transplantation in Myelofibrosis.

Authors:  Nicolaus Kröger
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 8.  Myelofibrosis-When Do We Select Transplantation or Non-transplantation Therapeutic Options?

Authors:  Auro Viswabandya; Rebecca Devlin; Vikas Gupta
Journal:  Curr Hematol Malig Rep       Date:  2016-02       Impact factor: 3.952

Review 9.  An update on allogeneic hematopoietic progenitor cell transplantation for myeloproliferative neoplasms in the era of tyrosine kinase inhibitors.

Authors:  K Adekola; U Popat; S O Ciurea
Journal:  Bone Marrow Transplant       Date:  2014-08-04       Impact factor: 5.483

Review 10.  Fifty years of melphalan use in hematopoietic stem cell transplantation.

Authors:  Ulas D Bayraktar; Qaiser Bashir; Muzaffar Qazilbash; Richard E Champlin; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2012-08-24       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.